Does Extended Interval Dosing Natalizumab Preserve Effectiveness in Multiple Sclerosis? A 7 Year-Retrospective Observational Study

The extended interval dosing (EID) of natalizumab has been suggested to be associated with a reduced risk of progressive multifocal leukoencephalopathy (PML) and short-term preservation of efficacy but its long-term effectiveness remain unknown. We aimed to determine the long-term effectiveness and...

Descripción completa

Detalles Bibliográficos
Autores principales: Riancho, Javier, Setien, Sonia, Sánchez de la Torre, Jose Ramón, Torres-Barquin, Marta, Misiego, Mercedes, Pérez, José Luis, Castillo-Triviño, Tamara, Menéndez-García, Cristina, Delgado-Alvarado, Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8027344/
https://www.ncbi.nlm.nih.gov/pubmed/33841397
http://dx.doi.org/10.3389/fimmu.2021.614715

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8027344/
https://www.ncbi.nlm.nih.gov/pubmed/33841397
http://dx.doi.org/10.3389/fimmu.2021.614715

Ejemplares similares